CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...